| Factor | Women (n=83) | Men (n=52) | P value |
|---|---|---|---|
| Median (25th-75thpercentile) | |||
| Age | 55.1 (46.8-63) | 56.6 (50-65.7) | 0.419* |
| BMI | 27.9 (24.9-35) | 30.1 (26.8-33.3) | 0.181# |
| Pso duration/ PsA duration (years) | 8.3 (3.9-24.5)/ 2.4 (0-5.7) | 14.3 (4.7-22.7)/ 2.8 (0-6.4) | 0.451# /0.605# |
| Smoking (Packyears) | 15 (5-30) | 27.5 (0-46) | 0.002# |
| TJC/SJC | 11 (4-16)/ 10 (5-17) | 3 (0-13)/ 3 (0-14) | 0.001#/0.013# |
| VASPain/ VASGA | 6 (5-8)/ 5 (3-6) | 5 (1-6)/ 4 (2-5) | <0.001*/0.121* |
| CRP/ ESR | 1.4 (0.4-3.2)/20(11-33) | 1.1 (0.2-2.7)/ 11 (7-18) | 0.398#/0.001# |
| BSA/PASI | 0 (0-2)/0(0-2) | 2 (0-6)/1(0-4.8) | 0.139#/0.258# |
| DAPSA | 33 (24.1-45) | 18 (9.3-45) | 0.006# |
| n (%) | |||
| Enthesitis/ Dactylitis | 27 (32.5)/ 20 (24.1) | 7 (13.5)/ 10 (19.2) | 0.013***/ 0.508*** |
| Dyslipidemia | 33 (40.2) | 31 (59.6) | 0.029*** |
| Liver | 3 (3.6) | 7 (13.5) | 0.046** |
| Eyes | 0 (0) | 3 (5.8) | 0.055** |
| Uricemia | 3 (3.6) | 8 (15.4) | 0.023** |
| Depression or anxiety | 16 (19.3) | 11 (21.1) | 0.817*** |
| CAD | 2 (2.4) | 12 (23.1) | <0.001** |
| DM | 14 (16.9) | 12 (23.1) | 0.392 |
| MDA | 3 (3.6) | 14 (26.9) | <0.001 |
*: T-test with unequal variances; #: Mann-Whitney test; **: Fisher’s exact test; ***: Pearson chi2 test;
Pso: Psoriasis; PsA: Psoriatic arthritis; BMI: Body mass index; TJC: Tender joint count; SJC: Swollen joint count; VASPain: Visual analogue scale 0-10 for pain; VASGA: Visual analogue scale 0-10 for general assessement; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; BSA: Body surface area; PASI: Psoriasis area severity index; DAPSA: Disease activity in psoriatic arthritis; CAD: Coronary artery disease; DM: Diabetes mellitus; MDA: Minimal disease activity;